Skip to main content
Signal8

Yu John S

SEC insider (Form 3/4/5 filer). CIK 0001550545. CEO and Chairman at Kairos Pharma, LTD. (KAPA). 3 reported Form 4/5 transactions since Sep 2024; latest on Oct 8, 2025. Located in LOS ANGELES, CA.

Companies Yu John S has filed insider reports for

  • Kairos Pharma, LTD. (KAPA): Director, Officer, 10% Owner, CEO and Chairman
Yu John S profile photo

Yu John S

CIK: 0001550545

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Kairos Pharma, LTD. logo
KAPA

Kairos Pharma, LTD.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Kairos Pharma, LTD. logo
    KAPA

    Kairos Pharma, LTD.

    Oct 8, 2025
    Award
    Direct
    190.8K shares-
  • Kairos Pharma, LTD. logo
    KAPA

    Kairos Pharma, LTD.

    Jan 1, 2025
    Award
    Direct
    14K shares-
  • Kairos Pharma, LTD. logo
    KAPA

    Kairos Pharma, LTD.

    Nov 20, 2024
    Purchase
    Direct
    4K shares at avg. $1.44$6K

1-3 of 3